Literature DB >> 19447436

Factors predicting prostatic biopsy Gleason sum under grading.

Danielle A Stackhouse1, Leon Sun, Florian R Schroeck, Jayakrishnan Jayachandran, Arthur A Caire, Cyril O Acholo, Cary N Robertson, David M Albala, Thomas J Polascik, Craig F Donatucci, Kelly E Maloney, Judd W Moul.   

Abstract

PURPOSE: We determined clinical factors affecting the under grading of biopsy Gleason sum compared with prostatectomy pathology and developed a model predicting the probability of under grading.
MATERIALS AND METHODS: We analyzed a cohort of 1,701 patients treated for prostate cancer at our institution between 1988 and 2007 with complete biopsy and pathological data available. Patients with a biopsy Gleason sum of 7 or less were included in our analysis. Cases were categorized as under graded or not under graded by comparing biopsy and radical prostatectomy Gleason sums. Logistic regression was used to determine the predictors of under grading based on clinical variables (race, age at diagnosis, body mass index, prostate weight, diagnostic prostate specific antigen, biopsy positive-to-total core ratio, maximal cancer percent in positive cores and time from diagnosis to surgery). A nomogram was developed to calculate the probability of under grading. Results were validated using bootstrapping.
RESULTS: Under grading occurred in 46.6% of our cohort. Significant variables predicting under grading were age at diagnosis, biopsy Gleason sum, diagnostic prostate specific antigen, prostate weight, biopsy positive-to-total core ratio and maximal percent of cancer in cores (p <0.05). Nomogram predictive accuracy was 72.4%.
CONCLUSIONS: The risk of Gleason sum under grading can be predicted to a satisfactory level using our nomogram. Predicting under grading would improve patient consulting and identify those who should consider repeat biopsy, ultimately enhancing the accuracy of prostate cancer diagnosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19447436     DOI: 10.1016/j.juro.2009.02.127

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

1.  Clinical and pathological variables that predict changes in tumour grade after radical prostatectomy in patients with prostate cancer.

Authors:  Stavros Sfoungaristos; Petros Perimenis
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

2.  Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer.

Authors:  Hiten D Patel; Zhaoyong Feng; Patricia Landis; Bruce J Trock; Jonathan I Epstein; H Ballentine Carter
Journal:  J Urol       Date:  2013-09-20       Impact factor: 7.450

3.  A narrowing range of bone scan in newly diagnosed prostate cancer patients: A retrospective comparative study.

Authors:  Berat Cem Özgür; Sinan Gültekin; Musa Ekici; Demet Yılmazer; Murat Alper
Journal:  Urol Ann       Date:  2015 Apr-Jun

4.  Does the time from biopsy to radical prostatectomy affect Gleason score upgrading in patients with clinical t1c prostate cancer?

Authors:  Muzaffer Eroglu; Omer Gokhan Doluoglu; Hasmet Sarici; Onur Telli; Berat Cem Ozgur; Selen Bozkurt
Journal:  Korean J Urol       Date:  2014-06-16

Review 5.  Limitations and Prospects for Diffusion-Weighted MRI of the Prostate.

Authors:  Roger Bourne; Eleftheria Panagiotaki
Journal:  Diagnostics (Basel)       Date:  2016-05-27

6.  Re; Singh S, Patil S, Tamhankar AS, Ahluwalia P, Gautam G. Low-risk prostate cancer in India: Is active surveillance a valid treatment option? Indian J Urol 2020;36:184-90.

Authors:  Aditya P Sharma; Kapil Chaudhary; Sudheer K Devana
Journal:  Indian J Urol       Date:  2020-10-01

7.  Combined Systematic and MRI-US Fusion Prostate Biopsy Has the Highest Grading Accuracy When Compared to Final Pathology.

Authors:  Iulia Andras; Emanuel Darius Cata; Andreea Serban; Pierre Kadula; Teodora Telecan; Maximilian Buzoianu; Maria Bungardean; Dan Vasile Stanca; Ioan Coman; Nicolae Crisan
Journal:  Medicina (Kaunas)       Date:  2021-05-22       Impact factor: 2.430

8.  A nomogram to predict Gleason sum upgrading of clinically diagnosed localized prostate cancer among Chinese patients.

Authors:  Jin-You Wang; Yao Zhu; Chao-Fu Wang; Shi-Lin Zhang; Bo Dai; Ding-Wei Ye
Journal:  Chin J Cancer       Date:  2014-02-14

9.  Refining treatment for the men who need it: lessons from the PIVOT trial.

Authors:  Michael R Abern; Matvey Tsivian; Thomas J Polascik
Journal:  Transl Androl Urol       Date:  2013-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.